Akebia Therapeutics, Inc. (AKBA) scores 40 out of 100 on boothcheck's 11-model valuation framework. Verdict: Strong Avoid The estimated fair value is $2.52, representing a 80% margin of safety. Quantitative score: 58/100. Qualitative score: 20/100.
Analysis includes bear, base, and bull fair value targets using DCF, Graham, regression, and 8 other valuation models.